Use: Labeled indications
- INDICATIONS AND USAGE Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused…
Full indications and usage US FDA label
INDICATIONS AND USAGE Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis).
The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin.
Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp.
(dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms.
A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.
Contraindications
- Previous hypersensitivity to any penicillin
Contraindications (US label) US FDA label
CONTRAINDICATIONS A history of a previous hypersensitivity reaction to any of the penicillins is a contraindication.
Dosing: Adult
- Respiratory tract and soft tissue (40 kg or more): 250 to 500 mg IV or IM every 6 hours
- Gastrointestinal and genitourinary (40 kg or more): 500 mg every 6 hours
- Bacterial meningitis: 150 to 200 mg/kg/day divided every 3 to 4 hours
- Gonococcal urethritis (men): Two 500 mg doses 8 to 12 hours apart
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Infections of the respiratory tract and soft tissues. Patients weighing 40 kg (88 lbs) or more: 250 mg to 500 mg every 6 hours. Patients weighing less than 40 kg (88 lbs): 25 to 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals. Infections of the gastrointestinal and genitourinary tracts (including those caused by Neisseria gonorrhoeae in females).
Patients weighing 40 kg (88 lbs) or more: 500 mg every 6 hours. Patients weighing less than 40 kg (88 lbs): 50 mg/kg/day in equally divided doses at 6 to 8 hour intervals. In the treatment of chronic urinary tract and intestinal infections, frequent bacteriological and clinical appraisal is necessary. Smaller doses than those recommended above should not be used.
Higher doses should be used for stubborn or severe infections. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy. Urethritis in males due to N. gonorrhoeae. Adults - Two doses of 500 mg each at an interval of 8 to 12 hours.
Treatment may be repeated if necessary or extended if required. In the treatment of complications of gonorrheal urethritis, such as prostatitis and epididymitis, prolonged and intensive therapy is recommended. Cases of gonorrhea with a suspected primary lesion of syphilis should have darkfield examinations before receiving treatment.
In all other cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of four months. The doses for the preceding infections may be given by either the intramuscular or intravenous route. A change to oral ampicillin may be made when appropriate. Bacterial Meningitis Adults and children - 150 to 200 mg/kg/day in equally divided doses every 3 to 4 hours.
(Treatment may be initiated with intravenous infusion therapy and continued with intramuscular injections.) The doses for other infections may be given by either the intravenous or intramuscular route. Neonates (less than or equal to 28 days of postnatal age) -Dosage should be based on Gestational age and Postnatal age according to Table 1.
TABLE 1: Dosage in Neonates (less than or equal to 28 days of postnatal age) for Bacterial Meningitis and Septicemia: Gestational age (weeks) Postnatal age (days) Dosage less than or equal to 34 less than or equal to 7 100 mg/kg/day in equally divided doses every 12 hours less than or equal to 34 greater than or equal to 8 and less than 28 150 mg/kg/day in equally divided doses every 12 hours greater than 34 less than or equal to 28 150 mg/kg/day inequally divided doses every 8 hours Septicemia Adults and children - 150 to 200 mg/kg/day. Start with intravenous administration for at least three days and continue with the intramuscular route every 3 to 4 hours.
Neonates (less than or equal to 28 days of postnatal age) - Dosage should be based on Gestational age and Postnatal age according to Table 1 (above). Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained.
A minimum of 10-days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis. DIRECTIONS FOR USE Use only freshly prepared solutions. Intramuscular and intravenous injections should be administered within one hour after preparation since the potency may decrease significantly after this period.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. For Intramuscular Use – Dissolve contents of a vial with the amount of Sterile Water for Injection, USP, or Bacteriostatic Water for Injection, USP, listed in the table below: NDC 72603 Label Claim Recommended Amount of Diluent Withdrawable Volume Concentration (in mg/mL) 221-10 500 mg 1.8 mL 2 mL 250 mg 363-10 1 gram 3.5 mL 4 mL 250 mg 454-23 2 grams 6.8 mL 8 mL 250 mg While Ampicillin for Injection, USP, 1 g and 2 g, are primarily for intravenous use, they may be administered intramuscularly when the 250 mg or 500 mg vials are unavailable.
In such instances, dissolve in 3.5 or 6.8 mL Sterile Water for Injection, USP, or Bacteriostatic Water for Injection, USP, respectively. The resulting solution will provide a concentration of 250 mg per mL. For Direct Intravenous Use – Add 5 mL Sterile Water for Injection, USP, or Bacteriostatic Water for Injection, USP to the 250 mg and 500 mg vials and administer slowly over a 3- to 5- minute period.
Ampicillin for Injection, USP, 1 g or 2 g may also be given by direct intravenous administration. Dissolve in 7.4 or 14.8 mL Sterile Water for Injection, USP, or Bacteriostatic Water for Injection, USP, respectively, and administer slowly over at least 10 to 15 minutes. CAUTION: More rapid administration may result in convulsive seizures.
For Administration by Intravenous Drip – Reconstitute as directed above (For Direct Intravenous Use) prior to diluting with Intravenous Solution. Stability studies on ampicillin sodium at several concentrations in various intravenous solutions indicate the drug will lose less than 10% activity at the temperatures noted for the time periods stated.
Room Temperature (25°C) Diluent Concentrations Stability Periods Sterile Water for Injection up to 30 mg/mL 8 hours 0.9% Sodium Chloride Injection, USP up to 30 mg/mL 8 hours 5% Dextrose Injection, USP 10 to 20 mg/mL 1 hour 5% Dextrose Injection, USP up to 2 mg/mL 2 hours 5% Dextrose and 0.45% Sodium Chloride Injection, USP up to 2 mg/mL 2 hours Lactated Ringer’s Injection, USP up to 30 mg/mL 8 hours Refrigerated (4°C) Diluent Concentrations Stability Periods Sterile Water for Injection 30 mg/mL 48 hours Sterile Water for Injection up to 20 mg/mL 72 hours 0.9% Sodium Chloride Injection, USP 30 mg/mL 24 hours 0.9% Sodium Chloride Injection, USP up to 20 mg/mL 48 hours Lactated Ringer’s Injection, USP up to 30 mg/mL 24 hours 5% Dextrose Injection, USP up to 20 mg/mL 1 hour 5% Dextrose and 0.45% Sodium Chloride Injection, USP up to 10 mg/mL 1 hour Only those solutions listed above should be used for the intravenous infusion of Ampicillin for Injection, USP. The concentrations should fall within the range specified.
The drug concentration and the rate and volume of the infusion should be adjusted so that the total dose of ampicillin is administered before the drug loses its stability in the solution in use.
Dosing: Altered kidney function
Ampicillin is excreted largely unchanged in urine. The US injection label gives no kidney dose adjustment and no dialysis dosing; its overdose section says ampicillin-class antibiotics are removed by hemodialysis but not by peritoneal dialysis. Dosing in kidney impairment needs specialist input.
Kidney function measure: Label gives no kidney measure or bands.
Show full dosing details
- CrCl ≥60 mL/min
- Usual dose (label gives no kidney adjustment).
- CrCl 30–59 mL/min
- The label gives no kidney dose adjustment. Ampicillin is excreted largely unchanged in urine, so levels rise as kidney function falls. Specialist input.
- CrCl 15–29 mL/min
- The label gives no kidney dose adjustment. Ampicillin is excreted largely unchanged in urine, so levels rise as kidney function falls. Specialist input.
- CrCl <15 mL/min (not on dialysis)
- The label gives no kidney dose adjustment. Ampicillin is excreted largely unchanged in urine, so levels rise as kidney function falls. Specialist input.
- Hemodialysis (intermittent)
- Ampicillin-class antibiotics are removed by hemodialysis (label overdose section); no dose is given. Time doses after the session. Specialist input.
- Peritoneal dialysis
- Not removed by peritoneal dialysis (label overdose section); the label gives no dose. For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 4 g daily; continuous maintenance dose 125 mg/L in each exchange (no loading dose listed). ISPD 2022 notes that intraperitoneal ampicillin is not recommended for enterococcal peritonitis. Specialist input.
- CRRT
- Not in label; the cited CRRT review (Li 2020) gives no regimen for this drug. Specialist input.
- Dialyzable? Hemodialysis: yes. Peritoneal dialysis: no (label overdose section, for ampicillin-class antibiotics). About 20% protein bound.
- Monitoring Kidney function; neurologic toxicity at high doses with kidney impairment; rash; diarrhea (CDAD).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual pediatric dose (label).
- eGFR 30–59
- No pediatric kidney dosing in label. Specialist input.
- eGFR 15–29
- No pediatric kidney dosing in label. Specialist input.
- eGFR <15 (not on dialysis)
- No pediatric kidney dosing in label. Specialist input.
- Hemodialysis (intermittent)
- No pediatric kidney dosing in label. Specialist input.
- Peritoneal dialysis
- No pediatric kidney dosing in label. Specialist input.
- CRRT
- No pediatric kidney dosing in label. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Dosing: Pediatric
- Approved ages
- Neonates and children (label).
- Usual dose
- Neonates (28 days or younger), meningitis or septicemia, by gestational and postnatal age (label Table 1): 34 weeks or less and 7 days or less, 100 mg/kg/day every 12 hours; 34 weeks or less and 8 to under 28 days, 150 mg/kg/day every 12 hours; over 34 weeks, 150 mg/kg/day every 8 hours. Under 40 kg: respiratory and soft tissue 25 to 50 mg/kg/day divided every 6 to 8 hours; gastrointestinal and genitourinary 50 mg/kg/day divided every 6 to 8 hours; bacterial meningitis 150 to 200 mg/kg/day divided every 3 to 4 hours (label).
- Maximum dose
- As above (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use Guidelines for the administration of these drugs to children, including neonates are presented in DOSAGE AND ADMINISTRATION section.
Dosage forms
Philippines
- Powder for injection: 1 g, 100 mg, 250 mg, 250 mg/vial, 500 mg
- Powder for solution for injection: 250 mg, 500 mg
- Capsule: 250 mg, 500 mg
- Sterile powder for injection: 1 g, 250 mg, 500 mg
- Mg powder for injection
- Powder for lnjection: 1 g
Registered products in the Philippines
111 products registered with the Food and Drug Administration (FDA) Philippines list Ampicillin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Ampiciilin (As Sodium) (2 products). Products registered under these spellings are included in the table and marked.
All registered products111
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AltozinAmpicillin Sodium | 250 mg Powder for Injection (IM/IV)Type II Glass Vial x 250 mg Box of 1’s | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Altomed Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | Ampicillin Sodium | Sep 10, 2027 | |
Ambacil 1Ampicillin (as sodium) | 1 g Powder for Injection (IM/IV)USP Type III Clear Glass Vial with Rubber stopper and pink flip-off seal (Box of 1's) | Rx | Celogen Pharma Pvt. LtdIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8647-01 | Oct 4, 2028 | |
Ambilin 1000Ampicillin (as sodium) | 1 g Powder for Injection (I.M./I.V.)7 mL moulded vial with rubber stopper and aluminum cap (Box of 10’s) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | AMB HK Enterprises Inc. | DRP-8595 | Dec 20, 2029 | |
Ambilin 500Ampicillin (as sodium) | 500 mg Powder for Injection (I.M./I.V.)7 mL moulded vial with rubber stopper and aluminum cap (Box of 10’s) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | AMB HK Enterprises Inc. | DRP-8594 | Dec 20, 2029 | |
AmbipenAmpicillin (as Sodium) | 500 mg Powder for Injection (I.M./I.V.)USP Type III clear glass vial with butyl rubber stopper (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Ambica International CorporationTrader: Gnana Life Sciences Pvt. Ltd. | DRP-5091 | Feb 12, 2029 | |
AmgramAmpicillin (as trihydrate) | 250 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DR-XY31405 | Mar 30, 2028 | |
Ampi-1Ampicillin (as sodium) | 1 g Powder For Injection (I.M./I.V.)7mL USP Type I Borosilicare, clear transparent glass vial with butyl rubber stopper and aluminum seal (Box of 5's and 10's) | Rx | NORTH CHINA PHARMACEUTICAL CO., LTD.China | AGLOBAL CARE, INC. | DRP-6136 | Mar 13, 2029 | |
Ampi-500Ampicillin (as sodium) | 500 mg Powder for Injection (IM/IV)7-mL capacity clear transparent glass vial with rubber stopper and aluminum flip-off cap (Box of 10's) | Rx | North China Pharmaceutical Co., Ltd.China | Aglobal Care, Inc. | DRP-15632 | Aug 13, 2029 | |
AmpibetAmpicillin (as sodium) | 250 mg Powder for Solution for Injection (IM/IV)7.5 mL -capacity USP type III glass vial with bromo butyl rubber stopper and green aluminum flip-off seal (Box of 10 vials) | Rx | Inject Care Parenterals Pvt. Ltd.India | Better Option Pharmaceuticals Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-12948-01 | Nov 11, 2027 | |
AmpibetAmpicillin (as sodium) | 500 mg Powder for Solution for Injection (IM/IV)7.5 mL-capacity USP type III glass vial bromo butyl rubber stopper and aluminum brown flip-off seal (Box of 10 vials) | Rx | Inject Care Parenterals Pvt. Ltd.India | Better Option St., Bangkal, Makati City, Metro ManilaImporter: Suhitas Pharmaceuticals Inc. | DRP-12949-01 | Nov 11, 2027 | |
Ampic-100Ampicillin (as sodium) | 100mg Powder for Injection (I.M./I.V)USP Type I White Glass Vial (Box of 1's) | Rx | 2 World Laboratories, IndiaIndia | 2 World Traders Subic Inc. | DR-XY38122 | Jun 23, 2030 | |
Ampic-500Ampicillin (as sodium) | 500mg Powder for Injection (I.M/I.V)USP Type I glass vial (Box of 1's) | Rx | 2 World Laboratories, IndiaIndia | 2 World Traders Subic Inc. | DR-XY38121 | Jun 23, 2030 | |
Ampicelo 250Ampicillin (as sodium) | 250 mg Powder for Injection (I.M./I.V.)7.5 mL USP Type III Clear Glass Vial (Box of 1's, 10's, and 50's) | Rx | Celogen Pharma Pvt. Ltd.India | Pharmastar Int'l Trading Corp. | DRP-5868 | Jul 15, 2028 | |
AMPICENT-1Ampicillin (as sodium) | 1 g Powder For Injection (I.M./I.V.)7mL USP Type I Borosilicare, clear transparent glass vial with butyl rubber stopper and aluminum seal (Box of 5's and 10's) | Rx | NORTH CHINA PHARMACEUTICAL CO., LTD.China | CENTRAL WEST MEDICALE INC.Importer: AGLOBAL CARE, INC. | DRP-6136-04 | Mar 13, 2029 | |
Ampicent-500Ampicillin (as Sodium) | 500 mg Powder for Injection (IM/IV)Type III Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 1's (Box of 1's) | Rx | Injectcare Parenterals Pvt. Ltd.India | Central West Medicale Inc.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-10859-01 | Dec 9, 2031 | |
AmpicinAmpicillin (as Sodium) | 250 mg Powder for Injection (I.M./I.V.)Individually boxed flint glass vial with rubber stopper and aluminum seal Box of 1's and 10's | Rx | Sandoz GmbHAustria | Unilab, Inc.Importer: Sandoz Philippines Corporation | DRP-4565-01 | Feb 2, 2029 | |
AmpicinAmpicillin (as trihydrate) | 500 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Asian Antibiotics, Inc.Philippines | Trader: UNILAB, Inc. | DR-6676 | Jul 12, 2029 | |
AmpicinAmpicillin (As Sodium) | 500 mg Powder For Injection (IM/IV)Clear Colorless USP Type III Glass Vial with Rubber Stopper and Crimp Aluminum Seal x 5 mL (Box of l's and 10's) | Rx | Sandoz GmbHAustria | UNILAB, Inc.Importer: Sandoz Philippines Corporation | DRP-4575-01 | Dec 27, 2026 | |
AmpidenAmpicillin (as sodium) | 1 g Powder for Injection (I.M./I.V.)7 mL mould vial with rubber stopper and aluminum cap (Box of 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Cyden Medicale Trading Inc. | DRP-8595-02 | Dec 20, 2029 | |
AmpidenAmpicillin (as sodium) | 500 mg Powder for Injection (I.M./I.V.)7 mL mould vial with rubber stopper and aluminum cap (Box of 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Cyden Medicale Trading Inc.Importer: Amb Hk Enterprises Inc. | DRP-8594-02 | Dec 20, 2029 | |
AmpirichAmpicillin (as sodium) | 250 mg Powder for Solution for Injection (IM/IV)7.5 mL-capacity USP type III glass vial with bromo butyl rubber stopper and green aluminum flip-off seal (Box of 10 vials) | Rx | Inject Care Parenterals Pvt. Ltd.India | Medirich Pharma Distribution Corp.Importer: Orange Biotec Inc. | DRP-12948-02 | Nov 11, 2027 | |
Ampisaph-1000Ampicillin (as sodium) | 1 g Powder For Injection (IM/IV)10-mL capacity USP Type I Clear glass vial with gray bromobutyl rubber stopper and green flip-off seal (Box of 1's and 10's) | Rx | Bueno Salud Care (India) Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13853 | May 3, 2028 | |
Ampisaph-250Ampicillin (As Sodium) | 250 mg Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Green Aluminum Seal and Green Flip-off cap xl's (Box of l's and 10's) | Rx | Bueno Salud Care (India) Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-12636 | Sep 16, 2027 | |
Ampisaph-500Ampicillin (as sodium) | 500 mg Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Green Aluminum Seal and Green Flip-off cap x l's (Box of l's and 10's) | Rx | Bueno Salud Care (India) Pvt. Ltd.India | Lifesciences, Inc. | DRP-12635 | Sep 16, 2027 | |
Ampisave-1Ampicillin (as sodium) | 1 g Powder For Injection (I.M./I.V.)7mL USP Type I Borosilicate, clear transparent glass vial with butyl rubber stopper and aluminum seal (Box of 5's and 10's) | Rx | North China Pharmaceutical Co., LtdChina | Savelink Pharma And Trading Co.Importer: Aglobal Care, Inc. | DRP-6136-07 | Mar 13, 2029 | |
Ampisave-250Ampicillin (as sodium) | 250 mg Powder for Injection (IM/IV)Type III Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Aluminum Flip-off seal x 1's (Box of 10's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Savelink Pharma and Trading Co.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-10860-05 | Dec 9, 2026 | |
Ampisave-500Ampicillin (as sodium) | 500 mg Powder for Injection (IM/IV)7-mL capacity clear transparent glass vial with rubber stopper and aluminum flip-off cap (Box of 10's) | Rx | North China Pharmaceutical Co., Ltd.China | Savelink Pharma And Trading Co.Importer: Aglobal Care, Inc. | DRP-15632-01 | Aug 13, 2029 | |
AmpistarAmpicillin (as sodium) | 1g Powder for Injection (I.V./I.M.)USP Type III clear glass vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Pharmastar Int'l Trading Corp. | DRP-14465 | Sep 8, 2028 | |
Ampistar 250Ampicillin (as sodium) | 250 mg Powder for Injection (I.V./I.M.)USP Type III clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Pharmastar Int'l Trading Corp. | DRP-14772 | Jan 2, 2029 | |
Ampistar 500Ampicillin (as sodium) | 500 mg Powder for Injection (I.V./I.M.)USP Type III clear glass vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Pharmastar Int'l Trading Corp. | DRP-14466 | Sep 8, 2028 | |
AMPITEK-1Ampicillin (as Sodium) | 1g Powder for Injection (I.M./I.V.)7mL USP Type I Borosilicare, clear transparent glass vial with butyl rubber stopper and aluminum seal (Box of 5's and 10's) | Rx | NORTH CHINA PHARMACEUTICAL CO., LTD.China | UNITECHNIK VENTURES CORPORATIONImporter: AGLOBAL CARE, INC. | DRP-6136-03 | Mar 13, 2029 | |
Ampitek-250Ampicillin (as sodium) | 250 mg Powder for Injection (IM/IV)Type III Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 1's (Box of 1's) | Rx | Injectcare Parenterals Pvt. Ltd.India | Unitechnik Ventures CorporationImporter: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-10860-01 | Dec 9, 2026 | |
AmpitrexAmpicillin (as sodium) | 1g Powder for Injection (I.M./I.V.)Clear Glass Vial with Rubber Stopper and Aluminum Flip Off Seal x 1g (Box of 10's and 50's) | Rx | Harbin Pharmaceutical Group Co. Ltd General Pharm. FactoryChina | Endure Medical, Inc.Importer: Endure Medical Inc. | DR-XY33700 | Aug 2, 2027 | |
AmpitrexAmpicillin (as sodium) | 500mg Powder for Injection (I.M./I.V.)Clear Glass Vial with rubber stopper and aluminum seal (Box of 10's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm FactoryChina | Endure Medical, Inc. | DR-XY33691 | Aug 1, 2027 | |
AmpivexAmpicillin (as Sodium) | 1 g Powder for Injection (I.M./I.V.)Clear, colorless, type III glass vial 1 g in individual box Box of 10's | Rx | NORTH CHINA PHARMACEUTICAL CO., LTDChina | SANNOVEX PHARMACEUTICAL DISTRIBUTOR | DRP-2454 | Feb 25, 2029 | |
AmpivexAmpicillin (as Sodium) | 500 mg Powder for Injection (IM/IV)Clear Colorless Type III Glass Vial with Rubber Stopper and Blue Flip-off Seal in individual box / (Box of 10's) | Rx | North China Pharmaceutical Co., Ltd.China | Sannovex Pharmaceutical Distributor | DRP-2455 | Feb 26, 2031 | |
AmpivinAmpicillin (as sodium) | 1 g Powder for Injection (IM/IV)USP Type III Flint Vial with rubber stopper and aluminum flip off seal Box of 10’s | Rx | Inject Care Parenterals Pvt. Ltd.India | Amediqo Phils., Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-1618-02 | Sep 3, 2029 | |
AmpivinAmpicillin (as sodium) | 250 mg/vial Powder for Injection (IV/IM)USP Type III Clear Glass Vial with Blue Flip-off Seal (Box of 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Medhaus Pharma, IncorporatedImporter: Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-2223-03 | Apr 1, 2031 | |
AmpivinAmpicillin (as sodium) | 500 mg Powder for Injection (IM/IV)USP Type III flint glass vial with grey butyl rubber stopper and gold aluminum seal (Box of 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Amediqo Phils., Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-1617-03 | Sep 3, 2029 | |
Ampizar-250Ampicillin (As Sodium) | 250 mg Powder for Injection (IM/IV)Type III Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 1's (Box of 10's) | Rx | Injectcare Parenterals Pvt. Ltd.India | Dhan-Czar MarketingImporter: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-10860-04 | Dec 9, 2026 | |
Ampizar-500Ampicillin (as sodium) | 500 mg Powder for Injection (IM/IV)Type III Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 1's (Box of 10's) | Rx | Injectcare Parenterals Pvt. Ltd.India | Dhan-Czar MarketingImporter: Aglobal Care, Inc.Trader: Antilla Lifesciences Pvt. Ltd. | DRP-10859-02 | Dec 9, 2031 | |
Amzellin-250Ampicillin (as sodium) | 250 mg/vial Powder for Injection (IV/IM)USP Type III Clear Glass Vial with Blue Flip-off Seal (Box of 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Kodapharm Med Corp.Importer: Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-2223-05 | Apr 1, 2031 | |
Amzellin-500Ampicillin (as sodium) | 500 mg Powder for Injection (IM/IV)USP Type III flint glass vial with grey butyl rubber stopper and gold aluminum seal Box of 10’s | Rx | Inject Care Parenterals Pvt. Ltd.India | Kodapharm Med Corp.Importer: Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-1617-05 | Sep 3, 2029 | |
Amzellin-500Ampicillin (as sodium) | 500 mg Powder for Solution for Injection (IM/IV)7.5 mL-capacity USP type III glass vial with bromo butyl rubber stopper and aluminum brown flip-off seal (Box of 10 vials) | Rx | Inject Care Parenterals Pvt. Ltd.India | Kodapharm Med Corp.Importer: Orange Biotec Inc. | DRP-12949-03 | Nov 11, 2027 | |
Baamcillin-1000Ampicillin (as sodium) | 1 g Powder for Injection10 mL-capacity USP Type III clear glass vial with bromobutyl rubber stopper and green aluminum flip- off seal (Box of 1's) | Rx | INJECTCARE PARENTERALS PVT LTD.India | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-13974 | May 29, 2028 | |
BAAMCILLIN-250Ampicillin (As Sodium) | 250 mg Powder for Injection (Im/Iv)Type III Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal X 1’s (Box of 1’s, Box of 10’s and Box of 1’s in 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-10860 | Dec 9, 2031 | |
Baamcillin-500Ampicillin (As Sodium) | mg Powder for Injection (IM/IV)Type III Colorless Glass Vial With Gray Bromobutyl Rubber Stopper And Aluminum Flip-Off Seal x 1’s (Box of 1’s, 10’s and 1’s in 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-10859 | Dec 9, 2031 | |
Bacterad-500Ampicillin (as sodium) | 500 mg Powder for Injection (IM/IV)USP Type III Flint Glass Vial with Grey Butyl Rubber Stopper and Gold Aluminum Seal (Box of 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Ark Gen Pharma Corp.Importer: Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-1617-02 | Sep 3, 2029 | |
BlupenAmpicillin (as sodium) | 250 mg Powder for Injection (IM/IV)7.5 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Silver Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Blue Medceuticals Marketing Corp.Importer: Greencore Pharma, Inc. | DRP-13674-07 | Mar 24, 2028 | |
BlupenAmpicillin (as sodium) | 500 mg Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Red Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Blue Medceuticals Marketing Corp.Importer: Greencore Pharma, Inc. | DRP-13673-05 | Mar 24, 2028 | |
Celobac 500Ampicillin (as sodium) | 500 mg Powder for Injection (IM/IV)7.5 mL USP Type III Clear Glass Vial (Box of 1's, 10's and 50's) | Rx | Celogen Pharma Pvt. Ltd.India | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-5889-02 | Aug 6, 2028 | |
ChacilinAmpicillin (as sodium) | 250 mg Powder for Injection (IM/IV)Type III Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Aluminum Flip-off seal x 1's (Box of 1's, Box of 10's and Box of 1's in 10's) | Rx | Injectcare Parenterals Pvt. Ltd.India | Medirich Pharma Distribution Corp.Importer: Aglobal Care, Inc. | DRP-10860-03 | Dec 9, 2031 | |
CorpilynAmpicillin (as sodium) | 1 g Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni Medicolabs, Inc.India | Greencore Pharma, Inc. | DRP-13672 | Mar 24, 2028 | |
CorpilynAmpicillin (As Sodium) | 250 mg Powder for Injection (IM/IV)7.5 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Silver Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni Medicolabs, Inc.India | — | DRP-13674 | Mar 24, 2028 | |
CorpilynAmpicillin (As Sodium) | 500 mg Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Butyl Rubber | Rx | Uni Medicolabs, Inc.India | Greencore Pharma, Inc. | DRP-13673 | Mar 24, 2028 | |
DincilinAmpicillin (as Sodium) | 1 g Powder for Injection (IM/IV)USP Type III Clear Glass Vial with Rubber Stopper and Aluminum Seal (Box of 50's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | DNBG Pharmaceuticals Phils.Importer: Steinbach Products Inc. | DRP-6294-01 | Feb 3, 2027 | |
ElcilinAmpicillin (as Sodium) | 1 g Powder for Injection (IM/IV)USP Type III Flint Vial with Rubber Stopper and Aluminum Flip-Off Seal (Box of 10's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Ellebasy Medicale TradingImporter: Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-1618-01 | Sep 3, 2029 | |
ElcilinAmpicillin (as sodium) | 250 mg/vial Powder for Injection (IV/IM)USP Type III Clear Glass Vial with Blue Flip-off Seal (Box of 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Ellebasy Medicale TradingImporter: Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-2223-01 | Apr 1, 2031 | |
ElcilinAmpicillin (as sodium) | 500 mg Powder for Injection (IM/IV)USP Type III Flint Glass Vial with Grey Butyl Rubber Stopper and Gold Aluminum Seal (Box of 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Ellebasy Medicale TradingImporter: Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-1617-01 | Sep 3, 2029 | |
Eurozyllin 1000Ampicillin (as sodium) | 1 g Powder for Injection (IM/IV)10 mL Type 1 Clear Glass Vial with Gray Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Euro-Care Products PhilippinesImporter: Greencore Pharma Inc. | DRP-13672-03 | Mar 24, 2028 | |
Eurozyllin 250Ampicillin (as sodium) | 250 mg Powder for Injection (IM/IV)7.5 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Silver Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni Medicolabs, Inc.India | Euro-Care Products PhilippinesImporter: Greencore Pharma, Inc. | DRP-13674-03 | Mar 24, 2028 | |
Eurozyllin 500Ampicillin (as sodium) | 500 mg Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Rubber Stopper and Red Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | UNI Medicolabs, Inc.India | Euro-Care Products PhilippinesImporter: Greencore Pharma Inc. | DRP-13673-03 | Mar 24, 2028 | |
ExcillinAmpicillin (as Sodium) | 1 g Powder for Injection (I.M./I.V.)Clear Glass Vial with rubber stopper and aluminum seal Box of 1's and 10's | Rx | Sandoz GmbHAustria | Importer: Sandoz Philippines Corporation | DRP-7226 | Mar 30, 2029 | |
ExcillinAmpicillin (as Sodium) | 250 mg Powder for Injection (I.M./I.V.)Flint Glass Vial with rubber stopper and aluminum seal Box of 1's, 10's, and 20's | Rx | Sandoz GmbHAustria | Importer: Sandoz Philippines Corporation | DRP-4565 | Feb 2, 2029 | |
ExcillinAmpicillin (As Sodium) | 500 mg Powder For Injection (I.M./I.V.)Clear Colorless USP Type III Glass Vial with Rubber Stopper and Crimp Aluminum Seal x 5 mL (Box of 1's and 10's) | Rx | Sandoz GmbHAustria | Importer: Sandoz Philippines Corporation | DRP-4575 | Dec 27, 2026 | |
Gidicilin 250Ampicillin (as sodium) | 250 mg Powder for Injection (IM/IV)7.5 mL Type I Clear Glass Vial With Gray Butyl Rubber Stopper and Silver Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Gdmed Pharma DistributorImporter: Greencore Pharma Inc. | DRP-13674-06 | Mar 24, 2028 | |
GiocillinAmpicillin (as sodium) | 1g Powder for Injection (I.M./I.V.)Molded glass vial with butyl rubber stopper and sealed with aluminum cap (Box of 1’s and 10's) | Rx | North China Pharmaceutical Co., Ltd.China | Euro-Care Products Philippines | DRP-11987 | May 27, 2027 | |
GiocillinAmpicillin (as sodium) | 500 mg Powder for Injection (I.M./I.V.)Molded glass vial with butyl rubber stopper and sealed with aluminum cap Box of 1's and 10's | Rx | NORTH CHINA PHARMACEUTICAL CO., LTD.China | EURO-CARE PRODUCTS PHILIPPINES | DRP-11988 | May 27, 2032 | |
GocillinAmpicillin (as sodium) | 1 g Powder For Injection (I.M./I.V.)7 mL USP Type I Borosilicare, clear transparent glass vial with butyl rubber stopper and aluminum seal (Box of 5's and 10's) | Rx | NORTH CHINA PHARMACEUTICAL CO., LTD.China | APPLIED PHARMACEUTICAL DISTRIBUTION INC.Importer: AGLOBAL CARE, INC. | DRP-6136-01 | Mar 13, 2029 | |
Gomillin 1Ampicillin (as sodium) | 1 g Powder for Injection (I.M./I.V.)7 mL mould vial with rubber stopper and aluminum cap (Box of 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: AMB HK Enterprises Inc. | DRP-8595-01 | Dec 20, 2029 | |
Gomillin 500Ampicillin (as sodium) | 500 mg Powder for Injection (I.M./I.V.)7 mL mould vial with rubber stopper and aluminum cap (Box of 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: AMB HK Enterprises Inc. | DRP-8594-01 | Dec 20, 2029 | |
Gopen 250Ampicillin (as sodium) | 250 mg Powder for Solution for Injection (IM/IV)7.5 mL - capacity USP type III glass vial with bromo butyl rubber stopper and green aluminium flip-off seal (Box of 10 vials) | Rx | Inject Care Parenterals Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Orange Biotec Inc. | DRP-12948-03 | Nov 11, 2027 | |
Gopen 250Ampicillin (as sodium) | 250 mg/vial Powder for Injection (IV/IM)USP Type III Clear Glass Vial with Blue Flip-off Seal (Box of 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-2223-04 | Mar 21, 2031 | |
Gopen 500Ampicillin (as sodium) | 500 mg Powder for Injection (IM/IV)USP Type III flint glass vial with grey butyl rubber stopper and gold aluminum seal (Box of 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Applied Pharmaceutical Distribution, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-1617-04 | Sep 3, 2029 | |
Gopen 500Ampicillin (as sodium) | 500 mg Powder for Solution for Injection (IM/IV)7.5 mL - capacity USP type III glass vial with bromo butyl rubber stopper and aluminum brown flip-off seal (Box of 10 vials) | Rx | Inject Care Parenterals Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Orange Biotec Inc. | DRP-12949-02 | Nov 11, 2027 | |
GopicinAmpicillin (as sodium) | 1 g Powder for Injection (IM / IV)10 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1’s (Box of 1's) | Rx | Uni Medicolabs, Inc.India | Applied Pharmaceutical Distribution Inc.Importer: Greencore Pharma, Inc. | DRP-13672-04 | Mar 24, 2028 | |
GopicinAmpicillin (as sodium) | 250 mg Powder for Injection (IM/IV)7.5 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Silver Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni Medicolabs, Inc.India | Applied Pharmaceutical Distribution Inc.Importer: Greencore Pharma, Inc. | DRP-13674-04 | Mar 24, 2028 | |
GopicinAmpicillin (as sodium) | 500 mg Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Red Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni Medicolabs, Inc.India | Applied Pharmaceutical Distribution Inc.Importer: Greencore Pharma Inc. | DRP-13673-04 | Mar 24, 2028 | |
250 mg Powder for Solution for Injection (IM/IV)7.5 mL-capacity USP type III glass vial with bromo butyl rubber stopper and green aluminium flip-off seal (Box of 10 vials) | Rx | Inject Care Parenterals Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-12948 | Nov 11, 2027 | ||
500 mg Powder For Solution For Injection (IM/IV)7.5 mL-capacity USP type III glass vial with bromo butyl rubber stopper and aluminum brown flip-off seal (Box of 10 vials) | Rx | Inject Care Parenterals Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Trader: N/A | DRP-12949 | Nov 11, 2027 | ||
LiferzinAmpicillin (as Sodium) | 1 g Powder for Injection (IM/IV)USP Type III Clear Glass Vial with Rubber Stopper and Aluminum Seal (Box of 50's and 10's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Steinbach Products Inc. | DRP-6294 | Feb 3, 2027 | |
LiferzinAmpicillin (as Sodium) | 250 mg Powder for Injection (IM/IV)Type III Flint vial x 7.5 mL with Rubber Stopper and Aluminum Seal with Blue flip-off cap (Box of 1's and 10's) | Rx | Reyoung Pharmaceutical Co. LtdChina | Philgen Pharmaceuticals Inc. | DRP-2019 | Mar 9, 2027 | |
LiferzinAmpicillin (as Sodium) | 500 mg Powder for Injection (IM/IV)Type III Flint Vial (7.5 mL) with Rubber Stopper and Aluminum Flip-off Seal (Box of 1's , 10's and 50's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Steinbach Products, Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-1972 | Mar 12, 2027 | |
NicocinAmpicillin (as Sodium) | 500 mg Powder for Injection (IM/IV)Type III Flint Vial (7.5 mL) with Rubber Stopper and Aluminum Flip-off Seal (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Thymed EnterprisesImporter: Steinbach Products, Inc. | DRP-1972-04 | Mar 12, 2027 | |
NoldicinAmpicillin (as sodium) | 500mg Powder For Injection (IM/IV)7.5ml plain glass vial packed with carton | Rx | Swiss Parenterals LimitedIndia | Applied Pharmaceutical Distribution, Inc. | DRP-14011 | Jun 5, 2028 | |
NoneAmpicillin (as Sodium) | 1g Powder for Injection (IM/IV)Colorless vial with Gray Rubber Stopper and Aluminum Flip-off Seal (Box of 10's) | Rx | Karnataka Antibiotics & Pharmaceuticals LimitedIndia | Phil. Pharmawealth, Inc. | DR-XY27437 | Apr 4, 2027 | |
NoneAmpicillin (as Sodium) | 1g Powder for Injection (IM/IV)USP Type III Clear Glass Vial with Rubber Stopper and Aluminum Seal (Box of 50's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Philgen Pharmaceuticals Inc.Importer: Steinbach Products, Inc. | DRP-6294-02 | Feb 3, 2027 | |
NoneAmpicillin (as Sodium) | 250 mg Powder for Injection (IM/IV)Colorless glass vial with rubber stopper and aluminum flip-off seal Box of 10 vials | Rx | Karnataka Antibiotics & Pharma Ltd.India | Phil. Pharmawealth, Inc. | DR-XY27454 | Apr 19, 2027 | |
NoneAmpicillin (as Trihydrate) | 500 mg CapsuleAlu/Clear PVC Blister Pack x 10's Box of 100's | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DR-XY31404 | Mar 30, 2028 | |
ObocilAmpicillin (as Sodium) | 100 mg Powder for Injection (IM/IV)USP Type II glass vial with green colored flip-off seal (Box of 10's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | Trader: Phil. Pharmawealth, Inc. | DR-XY34112 | Jan 3, 2028 | |
PentracinAmpicillin (as sodium) | 500 mg Powder for Injection (IM/IV)Clear Glass Vial with Grey Rubber Stopper x 7 mL (Box of 50's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Importer: Lakeside Pharmaceuticals Phil., Inc. | DR-XY28879 | Aug 20, 2030 | |
PolypenAmpicillin (as Sodium) | 1 g Sterile Powder for Injection (IM/IV)Type III Clear Glass Vial with Rubber Stopper and Green Aluminum Seal (Box of 10's) | Rx | YSS Laboratories Co., Inc.Philippines | Trader: The Cathay YSS Distributors Co., Inc. | DRP-1862 | Jul 6, 2029 | |
PolypenAmpicillin (as sodium) | 250 mg Sterile Powder for Injection (IM/IV)Colorless glass vial with rubber stopper and aluminium flip off seal (Box of 10's) | Rx | YSS Laboratories Co., Inc.Philippines | Trader: The Cathay YSS Distributors Co., Inc. | DRP-588 | Jul 6, 2027 | |
PolypenAmpicillin (as sodium) | 500 mg Sterile Powder for Injection (IM/IV)Clear Glass Vial with Rubber Stopper and Gold Aluminum Seal (Box of 10's) | Rx | YSS LABORATORIES CO., INC.Philippines | Trader: THE CATHAY YSS DISTRIBUTORS CO., INC. | DRP-403 | Jul 27, 2028 | |
QlinAmpicillin (as sodium) | 1 g Powder for Injection (IM/IV)10 mL Type 1 Clear Glass Vial with Gray Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap (Box of 1's) | Rx | Uni MedicolabsIndia | Ellebasy Medicale Group Inc.Importer: Greencore Pharma Inc. | DRP-13672-02 | Mar 24, 2028 | |
QLINAmpicillin (as sodium) | 250 mg Powder for Injection (IM/IV)7.5 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Silver Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Ellebasy Medicale Group Inc.Importer: Greencore Pharma Inc. | DRP-13674-01 | Mar 24, 2028 | |
QLINAmpicillin (as sodium) | 500 mg Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Red Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Ellebasy Medicale Group Inc.Importer: Greencore Pharma Inc. | DRP-13673-02 | Mar 24, 2028 | |
Ronzillin 1gAmpicillin (as sodium) | 1g Powder for Injection (I.M./I.V.)Molded glass vial with butyl rubber stopper and sealed with aluminum cap (Box of 1's and 10's) | Rx | North China Pharmaceutical Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-11987-01 | May 27, 2027 | |
Ronzillin 500Ampicillin (as sodium) | 500mg Powder for Injection (I.M./I.V.)Molded glass vial with rubber stopper and sealed with aluminum cap (Box of 1's and 10's) | Rx | North China Pharmaceutical Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-11988-1 | May 27, 2027 | |
ShinapenAmpicillin (as Sodium) | 500 mg Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial with Rubber Stopper and Yellow Flip-off Seal Box of 10's | Rx | Yung Shin Pharm. Ind. Co. Ltd. (Taichung Youth Factory III)China | Yung Shin (Philippines), Inc. | DR-XY19898 | May 11, 2027 | |
SodampenAmpicillin (as Sodium) | 1 g Powder For Injection (I.M./I.V.)Clear Glass Vial with Rubber Stopper and Blue Flip-off Seal Box of 1's and 10's | Rx | Vysali Pharmaceuticals Ltd.India | EURO-CARE PRODUCTS PHILIPPINES | DRP-590 | Jun 22, 2028 | |
SumpilinAmpicillin (as Sodium) | 1 g Powder for Injection (IM/IV)USP Type III Flint Vial x 10 mL with Rubber Stopper and Aluminum Flip-Off Seal (Box of 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-1618 | Sep 3, 2029 | |
SumpilinAmpicillin (as sodium) | 250 mg/vial Powder for Injection (IV/IM)USP Type III Clear Glass Vial with Blue Flip-off Seal (Box of 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-2223 | Mar 2, 2031 | |
SumpilinAmpicillin (as Sodium) | 500 mg Powder for Injection (IM/IV)USP Type III Flint Glass Vial with Grey Butyl Rubber Stopper and Gold Aluminum Seal (Box of 10’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-1617 | Sep 3, 2029 | |
TampicinAmpicillin (as sodium) | 250 mg Powder for Injection (IM/IV)7.5 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Silver Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Tamiga Pharmaceuticals SupplyImporter: Greencore Pharma, Inc. | DRP-13674-05 | Mar 24, 2028 | |
TAMPICINAmpicillin (as sodium) | 500 mg Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Red Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Tamiga Pharmaceuticals SupplyImporter: Greencore Pharma Inc. | DRP-13673-06 | Mar 24, 2028 | |
TripecilAmpicillin (as sodium) | 1 g Powder for lnjection (IM/IV)10 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Triple Tact Import & Export Corp.Importer: Greencore Pharma Inc. | DRP-13672-01 | Mar 24, 2028 | |
TripecilAmpicillin (as sodium) | 250 mg Powder for Injection (IM/IV)7.5 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Silver Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Triple Tact Import & Export Corp.Importer: Greencore Pharma Inc. | DRP-13674-02 | Mar 24, 2028 | |
TripecilAmpicillin (as sodium) | 500 mg Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Butyl Rubber Stopper and Red Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Triple Tact Import & Export Corp.Importer: Greencore Pharma Inc. | DRP-13673-01 | Mar 24, 2028 | |
VatacilAmpicillin Sodium | 250mg Powder for InjectionClear and Colorless Glass vial (Box of 10's) | Rx | YSS Laboratories Co., Inc.Philippines | Trader: Elin Pharmaceuticals, Inc. | DR-XY20729 | Jan 3, 2030 | |
VatacilAmpicillin Sodium | 500mg Powder for InjectionClear and Colorless Glass Vial (Box of 10's) | Rx | YSS Laboratories Co., Inc.Philippines | Trader: Elin Pharmaceuticals, Inc. | DR-XY20730 | Jan 3, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more apt to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens.
There have been well-documented reports of individuals with a history of penicillin hypersensitivity reactions who have experienced severe hypersensitivity reactions when treated with a cephalosporin. Before initiating therapy with a penicillin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, and other allergens.
If an allergic reaction occurs, the drug should be discontinued and appropriate therapy instituted. SERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE, OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Ampicillin for Injection, and may range in severity from mild diarrhea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Allopurinol | Minor | More skin rash with ampicillin-class drugs (label). | Usually no action; counsel. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
Drug Interactions The concurrent administration of allopurinol and ampicillin increases substantially the incidence of skin rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.
Adverse reactions
Common
- Rash, urticaria
- Diarrhea, nausea, glossitis, stomatitis
Serious
- Anaphylaxis
- Clostridioides difficile-associated diarrhea
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS As with other penicillins, it may be expected that untoward reactions will be essentially limited to sensitivity phenomena. They are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins and in those with a history of allergy, asthma, hay fever, or urticaria.
The following adverse reactions have been reported as associated with the use of ampicillin. Gastrointestinal Glossitis, stomatitis, black "hairy" tongue, nausea, vomiting, enterocolitis, pseudomembranous colitis, and diarrhea. (These reactions are usually associated with oral dosage forms.) Hypersensitivity Reactions Skin rashes and urticaria have been reported frequently.
A few cases of exfoliative dermatitis and erythema multiforme have been reported. Linear IgA bullous dermatosis has been reported. Anaphylaxis is the most serious reaction experienced and has usually been associated with the parenteral dosage form. Note: Urticaria, other skin rashes, and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids.
Whenever such reactions occur, ampicillin should be discontinued, unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to ampicillin therapy. Serious anaphylactic reactions require the immediate use of epinephrine, oxygen, and intravenous steroids. Liver A moderate rise in serum glutamic oxaloacetic transaminase (SGOT) has been noted, particularly in infants, but the significance of this finding is unknown.
Mild transitory SGOT elevations have been observed in individuals receiving larger (two to four times) than usual and oft-repeated intramuscular injections. Evidence indicates that glutamic oxaloacetic transaminase (GOT) is released at the site of intramuscular injection of ampicillin and that the presence of increased amounts of this enzyme in the blood does not necessarily indicate liver involvement.
Hemic and Lymphatic Systems Anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported during therapy with the penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. Central Nervous System Seizures To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx, LLC at 1- 800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Monitoring parameters
- Kidney function; neurologic toxicity at high doses with kidney impairment; rash; diarrhea (CDAD). Kidney
- Kidney function
- Rash
- Blood counts during long courses
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Category B Reproduction studies have been performed in laboratory animals at doses several times the human dose and have revealed no evidence of adverse effects due to ampicillin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Ampicillin is excreted in trace amounts in human milk. Therefore, caution should be exercised when ampicillin-class antibiotics are administered to a nursing woman.
Pharmacokinetics
Key PK parameters
| Protein binding | About 20% |
|---|---|
| Renal excretion kidney | Largely unchanged in urine (label) |
| Dialyzability kidney | Hemodialysis yes; peritoneal dialysis no (label) |
Ampicillin is excreted largely unchanged in the urine and its excretion can be delayed by concurrent administration of probenecid.
Due to maturational changes in renal function, ampicillin half-life decreases as postmenstrual age (a sum of gestational age and postnatal age) increases for infants with postnatal age of less than 28 days.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Ampicillin for Injection, USP diffuses readily into most body tissues and fluids. However, penetration into the cerebrospinal fluid and brain occurs only when the meninges are inflamed. Ampicillin is excreted largely unchanged in the urine and its excretion can be delayed by concurrent administration of probenecid.
Due to maturational changes in renal function, ampicillin half-life decreases as postmenstrual age (a sum of gestational age and postnatal age) increases for infants with postnatal age of less than 28 days. The active form appears in the bile in higher concentrations than those found in serum. Ampicillin is the least serum-bound of all the penicillins, averaging about 20% compared to approximately 60 to 90% for other penicillins.
Ampicillin for Injection, USP is well tolerated by most patients and has been given in doses of 2 grams daily for many weeks without adverse reactions.
Microbiology While in vitro studies have demonstrated the susceptibility of most strains of the following organisms, clinical efficacy for infections other than those included in the INDICATIONS AND USAGE section has not been demonstrated. Antibacterial Activity The following bacteria have been shown in in vitro studies to be susceptible to Ampicillin for Injection, USP: Gram-positive Bacteria Hemolytic and nonhemolytic streptococci Streptococcus pneumoniae Nonpenicillinase-producing staphylococci Clostridium spp.
B. anthracis Listeria monocytogenes Most strains of enterococci. Gram-negative Bacteria H. influenzae N. gonorrhoeae N. meningitidis Proteus mirabilis Many strains of Salmonella, Shigella, and E. coli. AMPICILLIN does not resist destruction by penicillinase. Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fds.gov/STIC.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Ampicillin 1 g Vial | ₱9.12–₱24.65Reference ₱11.19 | per vial | DPRI procurement range |
| Ampicillin 250 mg Vial | ₱7.22–₱37.85Reference ₱8.93 | per vial | DPRI procurement range |
| Ampicillin 500 mg Vial | ₱7.22–₱28.00Reference ₱8.21 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Ampicillin (as sodium salt) |
| PNF listing | Inj.: 250 mg, 500 mg and 1 g vial (IM, IV) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Ampicillin · NorthStar Rx, LLC [US FDA-approved label, version 2, November 6, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6772d650-9814-49e4-a4ec-0b1a97b837d1
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- NorthStar Rx, LLC. (2026). Ampicillin for injection, USP [Prescribing information; US FDA-approved label, ANDA062719, set ID 6772d650-9814-49e4-a4ec-0b1a97b837d1, version effective November 6, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6772d650-9814-49e4-a4ec-0b1a97b837d1
- Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .